公开(公告)号：US20180230429A1

公开(公告)日：2018-08-16

申请号：US15888897

申请日：2018-02-05

Applicant: TCR2 Therapeutics Inc.

Inventor： Patrick BAEUERLE ,  Gregory SIECZKIEWICZ ,  Robert HOFMEISTER

IPC: C12N5/0783 ,  C07K16/18 ,  C07K14/47 ,  A61P35/00

CPC classification number: C12N5/0638 ,  A61K2039/505 ,  A61K2039/572 ,  A61K2039/585 ,  A61K2039/6006 ,  A61P35/00 ,  C07K14/4748 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/70 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/70 ,  C12N5/0646

Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

公开(公告)号：US20180214612A1

公开(公告)日：2018-08-02

申请号：US15580678

申请日：2015-09-30

Applicant: INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY, CHINESE ACADEMY OF SCIENCES

Inventor： Jianwu DAI ,  Jie SUN ,  Bing CHEN ,  Zhifeng XIAO

IPC: A61L27/54 ,  C07K7/06 ,  C07K14/52 ,  A61K47/42 ,  A61L27/24 ,  A61L27/56 ,  A61L27/58 ,  A61K38/19 ,  A61K38/08

CPC classification number: A61L27/54 ,  A61K38/08 ,  A61K38/195 ,  A61K47/42 ,  A61L27/227 ,  A61L27/24 ,  A61L27/56 ,  A61L27/58 ,  A61L2300/25 ,  A61L2300/252 ,  A61L2300/414 ,  A61L2300/602 ,  A61L2430/20 ,  A61L2430/30 ,  A61L2430/38 ,  C07K7/06 ,  C07K14/522 ,  C07K2319/70

Abstract: Provided is a three dimensional tissue scaffold comprising a stem cell attracting element associated with a matrix, and fusion protein of stem cell attracting factor and collagen-binding domain, and methods of uses thereof.

公开(公告)号：US20180177864A1

公开(公告)日：2018-06-28

申请号：US15896871

申请日：2018-02-14

Applicant: Pfizer Inc.

Inventor： Ye Che ,  Philip Ralph Dormitzer ,  Alexey Vyacheslavovich Gribenko ,  Luke David Handke ,  Avvari Krishna Prasad ,  Xiayang Qiu ,  Mark Edward Ruppen ,  Xi Song ,  Kena Anne Swanson ,  Srinivas Kodali ,  Xin Xu ,  KariAnn Sweeney Efferen ,  Ping Cai ,  Kristin Rachael Tompkins ,  Lorna del Pilar Nunez

IPC: A61K39/155 ,  A61K39/12

CPC classification number: A61K39/155 ,  A61K39/12 ,  A61K2039/575 ,  C07K14/005 ,  C07K2319/02 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/40 ,  C07K2319/70 ,  C07K2319/735 ,  C12N7/00 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571

Abstract: The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

公开(公告)号：US20180170977A1

公开(公告)日：2018-06-21

申请号：US15739057

申请日：2016-06-23

Applicant: Spiber Technologies AB

Inventor： My Hedhammar

IPC: C07K14/435 ,  C12N15/62 ,  C12N5/00 ,  C08H1/00

CPC classification number: C07K14/43518 ,  C07K16/2839 ,  C07K2319/70 ,  C08H1/00 ,  C12N5/0068 ,  C12N15/62 ,  C12N2533/50

Abstract: A recombinant fusion protein is comprising a spider silk fragment and a cyclic RGD cell-binding motif with selectivity for integrins, such as for α5β1 integrins. The fusion protein is useful as a cell scaffold material and for the cultivation of cells displaying integrins on their cell surface.

公开(公告)号：US20180161369A1

公开(公告)日：2018-06-14

申请号：US15577280

申请日：2016-05-27

Applicant: Fred Hutchinson Cancer Research Center

Inventor： Stanley R. RIDDELL

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/70521 ,  C07K14/70575 ,  C07K14/70578 ,  C07K14/70596 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/80 ,  C07K2319/00 ,  C07K2319/70 ,  C12N5/0636 ,  C12N2510/00

Abstract: The present disclosure relates to compositions and methods for using cells having cellular immunotherapies comprising a composition of chimeric antigen receptor (CAR)-modified CD4+ T cells and a composition of CD8+ T cells modified with a distinct CAR in that the intracellular signaling component of the each CAR is different, wherein the modified CD4+ and CD8+ T cells have enhanced helper and effector functions, respectively, and together more effectively augment the immune response. Such cellular immunotherapies are useful in treating disease, such as cancer.

公开(公告)号：US20180148494A1

公开(公告)日：2018-05-31

申请号：US15541993

申请日：2016-01-07

Applicant: TherAchon ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE NICE SOPHIA ANTIPOLIS

Inventor： Elvire GOUZE ,  Stéphanie GARCIA

IPC: C07K14/71 ,  A61K9/00 ,  A61B5/00 ,  A61K38/17 ,  C07K14/47 ,  A61B6/00

CPC classification number: C07K14/71 ,  A61B5/4538 ,  A61B5/4848 ,  A61B6/505 ,  A61B6/508 ,  A61B2503/045 ,  A61B2503/06 ,  A61B2503/40 ,  A61K9/0019 ,  A61K38/00 ,  A61K38/1709 ,  A61K38/179 ,  C07K14/47 ,  C07K2319/30 ,  C07K2319/32 ,  C07K2319/33 ,  C07K2319/43 ,  C07K2319/70 ,  Y02A50/401

Abstract: The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.

公开(公告)号：US20180141972A1

公开(公告)日：2018-05-24

申请号：US15574481

申请日：2016-05-13

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH

Inventor： Saurabh Rajendra NIRANTAR ,  Farid John GHADESSY

IPC: C07K1/22 ,  C12N15/85

CPC classification number: C07K1/22 ,  C07K2319/21 ,  C07K2319/50 ,  C07K2319/70 ,  C12N15/85 ,  C12N2015/8518

Abstract: The present invention relates to an isolated polypeptide comprising (a) a protein of interest; (b) a first member of a pair of binding partners; (c) an affinity tag for immobilizing the polypeptide on a solid support; and (d) a modified endoprotease recognition site, wherein the modified endoprotease recognition site is located directly adjacent to the N-terminal amino acid of the protein of interest and comprises or only consists of the amino acid sequence N-terminal of the cleavage site of the native endoprotease recognition site. The present invention also relates to a nucleic acid encoding the above polypeptide and a host cell thereof, a method for isolating a protein of interest using the above polypeptide as a fusion partner and a protease fusion protein with the second member of the pair of binding partners and kits thereof. In addition, a method of degrading a target protein, a method of treatment and use of a fusion protease protein comprising a protease and a target protein binding element are also disclosed.

公开(公告)号：US20180135014A1

公开(公告)日：2018-05-17

申请号：US15857166

申请日：2017-12-28

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. ,  NATIONAL UNIVERSITY OF SINGAPORE

Inventor： Dario Campana ,  Yu-Hsiang Chang

IPC: C12N5/0783 ,  C07K14/705 ,  C12N5/00 ,  A61K35/17 ,  C07K14/725

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K38/00 ,  C07K14/705 ,  C07K14/7051 ,  C07K14/7056 ,  C07K2319/00 ,  C07K2319/70 ,  C12N5/0087 ,  C12N2510/00

Abstract: The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompasses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.

公开(公告)号：US20180127729A1

公开(公告)日：2018-05-10

申请号：US15551685

申请日：2016-02-17

Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.

Inventor： GIDEON FLEMINGER ,  OSNAT ASHUR-FABIAN ,  AVRAHAM DAYAN

IPC: C12N9/02 ,  A61K38/44 ,  A61K45/06 ,  A61K41/00 ,  A61K33/24

CPC classification number: C12N9/0051 ,  A61K33/24 ,  A61K38/07 ,  A61K38/44 ,  A61K41/0057 ,  A61K45/06 ,  C07K2319/70 ,  C12Y108/01004 ,  A61K2300/00

Abstract: The invention provides methods for treating a proliferative disease or disorder such as cancer by administering to patients suffering from the disease or disorder DLDH or a derivative thereof.

公开(公告)号：US20180119118A1

公开(公告)日：2018-05-03

申请号：US15809470

申请日：2017-11-10

Applicant: President and Fellows of Harvard College ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： Quan Lu ,  Qiyu Wang ,  Stanley N. Cohen

IPC: C12N9/16 ,  C07K7/06 ,  C07K14/47 ,  C12N9/22 ,  C12N9/00

CPC classification number: C12N9/16 ,  A61K9/1272 ,  A61K47/6455 ,  C07K7/06 ,  C07K14/4718 ,  C07K2319/00 ,  C07K2319/01 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/85 ,  C12N9/22 ,  C12N9/93 ,  C12N2810/85

Abstract: Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.